Methylphenidate controlled release - Purdue Pharma

Drug Profile

Methylphenidate controlled release - Purdue Pharma

Alternative Names: Aptensio XR; Biphentin Capsules; FOQUEST; Methylphenidate ER; Methylphenidate extended release; PRC-063

Latest Information Update: 07 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Purdue Pharma
  • Developer Purdue Pharma; Rhodes Pharmaceuticals
  • Class Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Dopamine uptake inhibitors; Monoamine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 21 Aug 2018 Purdue Pharma initiates a phase III trial for Attention-deficit hyperactivity disorder in USA (PO) (NCT03618030)
  • 07 Aug 2018 Purdue Pharma plans a phase III trial for Attention-deficit hyperactivity disorder in August 2018 (PO) (NCT03618030)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top